Overview

A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma

Status:
NOT_YET_RECRUITING
Trial end date:
2028-05-05
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, parallel-controlled integrated phase I/III clinical study to evaluate the efficacy, safety, PK, and immunogenicity of HLX13 and YERVOY in patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.
Phase:
PHASE3
Details
Lead Sponsor:
Shanghai Henlius Biotech